Company intelligence / Profile preview

Polyphenon Pharma

New York, New York, United Statespolyphenon.jp ↗

Ownership: Private
Development stage: Commercial

Overview

Polyphenon Pharma's lead botanical drug, Polyphenon E, achieved Phase III success as a topical ointment for genital and perianal warts (FDA-approved in 2006, marketed as Veregen), and demonstrated Phase I-II activity (orphan drug designation) in chronic lymphocytic leukemia and other indications. Oral forms have not reached commercialization, and the company is no longer active as of 2024.

Therapeutic areas: Infectious DiseasesOncologyGastroenterology
Modalities: Botanical drug
Industry: Biotech

Drug pipeline

2 assets

polyphenon

Commercial

Indications: Genital warts

1 more asset in the full pipeline.

Request access →

Partnerships

Mitsui Norin (parent/ingredient supplier)Bradley Pharmaceuticals (marketed Veregen in the US)

Beyond the preview

Go deeper on Polyphenon Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polyphenon Pharma.

Explore the full profile